Aging bone and osteoporosis - Strategies for preventing fractures in the elderly

被引:120
作者
Ettinger, MP
机构
[1] Reg Osteoporosis Ctr S Florida, Stuart, FL 34996 USA
[2] Radiant Res Stuart Florida, Stuart, FL 34996 USA
关键词
D O I
10.1001/archinte.163.18.2237
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
As the older population increases, the incidence of osteoporotic fractures is expected to, dramatically rise during the next few decades. Older patients are much more susceptible to fracture at any given bone mineral density (BMD) than are younger patients because of various factors, including the quality of aging bone, which involves more than BMD. Suppression of increased bone turnover by antiresorptive therapies, even with only small changes in BMD, can reduce fracture risk, especially in the lumbar spine. Bisphosphonate treatment can significantly reduce vertebral and nonvertebral fractures, including hip fractures, even in the very elderly. Prospective analyses show that risedronate therapy consistently and significantly reduces the risk of new morphometric vertebral fractures after 1 year in postmenopausal women. Post hoc analyses report significant reductions in the risk of 1 new clinical vertebral fracture after 6 months of risedronate therapy and after 1 year of alendronate therapy. Oral raloxifene therapy and salmon calcitonin nasal spray therapy have been shown to reduce the risk of vertebral fracture after 3 and 5 years, respectively, and post hoc data show a significant reduction in clinical vertebral fracture risk at 1 year with raloxifene use. However, neither raloxifene therapy nor calcitonin therapy reduce the risk of nonvertebral and hip fractures at currently approved doses. Bisphosphonates have been shown to be safe and efficacious with 7 years' risedronate sodium and 10 years' alendronate sodium data published, and bisphosphonates reduce bone turnover and increase BMD to a greater degree than raloxifene and calcitonin, which may partly account for their nonvertebral and hip fracture reduction effect. Therefore, bisphosphonate therapy with risedronate or alendronate should be considered in patients with low BMD at the hip and in older patients with osteoporosis and osteopenia, particularly those with an existing fracture.
引用
收藏
页码:2237 / 2246
页数:10
相关论文
共 115 条
[11]  
Buckley L, 2001, ARTHRITIS RHEUM, V44, P1496
[12]   Risk factors for increased bone loss in an elderly population - The Rotterdam Study [J].
Burger, H ;
de Laet, CEDH ;
van Daele, PLA ;
Weel, AEAM ;
Witteman, JCM ;
Hofman, A ;
Pols, HAP .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1998, 147 (09) :871-879
[13]   Does microdamage accumulation affect the mechanical properties of bone? [J].
Burr, DB ;
Turner, CH ;
Naick, P ;
Forwood, MR ;
Ambrosius, W ;
Hasan, MS ;
Pidaparti, R .
JOURNAL OF BIOMECHANICS, 1998, 31 (04) :337-345
[14]   Hormone replacement therapy in relation to breast cancer [J].
Chen, CL ;
Weiss, NS ;
Newcomb, P ;
Barlow, WN ;
White, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (06) :734-741
[15]   A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study [J].
Chesnut, CH ;
Silverman, S ;
Andriano, K ;
Genant, H ;
Gimona, A ;
Harris, S ;
Kiel, D ;
LeBoff, M ;
Maricic, M ;
Miller, P ;
Moniz, C ;
Peacock, M ;
Richardson, P ;
Watts, N ;
Baylink, D .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (04) :267-276
[16]   The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk [J].
Clowes, JA ;
Eastell, R .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 14 (02) :213-232
[17]  
Cohen S, 2000, ARTHRITIS RHEUM, V43, pS197
[18]  
Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO
[19]  
2-K
[20]   POPULATION-BASED STUDY OF SURVIVAL AFTER OSTEOPOROTIC FRACTURES [J].
COOPER, C ;
ATKINSON, EJ ;
JACOBSEN, SJ ;
OFALLON, WM ;
MELTON, LJ .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1993, 137 (09) :1001-1005